Indivior company information, Employees & Contact Information

Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th Yahoo Finance

Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation PR Newswire

Indivior Sets Q2 2025 Earnings Release and Live Webcast: Key Details for Investors Stock Titan

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users PR Newswire

Indivior Finalizes Exit from London Stock Exchange: What Shareholders Need to Know About Nasdaq-Only Trading Stock Titan

Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st Yahoo Finance

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained PR Newswire

Addiction Treatment Leader Indivior Sets Two Major September Investor Conference Appearances Stock Titan

Indivior Announces Q1 2025 Financial Results PR Newswire

Indivior Announces FY and Q4 2024 Financial Results PR Newswire

Indivior to Participate in Upcoming Investor Events – Company Announcement Financial Times

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer PR Newswire

Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance PR Newswire

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs PR Newswire

Indivior to Participate in Upcoming Investor Events PR Newswire

Indivior Announces Patrick Barry as Chief Commercial Officer PR Newswire

Indivior Appoints Tony Kingsley to the Board of Directors PR Newswire

Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes PR Newswire

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained Yahoo Finance

Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame PR Newswire

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection PR Newswire

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month PR Newswire

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review PR Newswire

Indivior (NASDAQ: INDV) sets Nov 13 fireside chat at Stifel 2025 Healthcare Conference Stock Titan

Indivior to Participate in the Stifel 2025 Healthcare Conference – Company Announcement Financial Times

Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone PR Newswire

Indivior To Acquire Opiant Pharmaceuticals PR Newswire

Indivior Agrees to Pay $385M Amid Monopoly Lawsuit Pharmaceutical Executive

The Identification of Naloxone-Related Drug Product Degradants ACS Publications

INDV - Indivior Latest Stock News & Market Updates Stock Titan

Indivior Takes Strategic Alignment Actions PR Newswire

Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder PR Newswire UK

Fighting apathy and lack of awareness in the struggle against substance use disorder Nature

Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder (OUD) and to Let People with OUD Know That They Can "Keep Moving Towards Recovery" PR Newswire

Indivior's RECOVER™ Study Finds Three-quarters of Patients with Moderate to Severe Opioid Use Disorder Who Received 12 monthly Injections of SUBLOCADE™ (Buprenorphine Extended-Release) Injection were Abstinent from Illicit Opioids One Year Late PR Newswire

Q&A with Indivior’s Christian Heidbreder PharmaLive

Indivior Launches National Campaign Informing People of an Additional Treatment MultiVu

FDA Approves First and Only Once-Monthly Injectable Buprenorphine Formulation to MultiVu